Olivier Keunen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8236076/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3749-3754.	7.1	552
2	Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nature Cell Biology, 2015, 17, 1556-1568.	10.3	423
3	EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis. Acta Neuropathologica, 2013, 125, 683-698.	7.7	127
4	Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas. Acta Neuropathologica, 2015, 129, 115-131.	7.7	122
5	Altered metabolic landscape in <scp>IDH</scp> â€mutant gliomasÂaffects phospholipid, energy, and oxidative stress pathways. EMBO Molecular Medicine, 2017, 9, 1681-1695.	6.9	111
6	EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation. Neuro-Oncology, 2016, 18, 1644-1655.	1.2	78
7	Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology. Acta Neuropathologica, 2020, 140, 919-949.	7.7	72
8	Molecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma. Oncotarget, 2016, 7, 31955-31971.	1.8	69
9	The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status. Neuro-Oncology, 2013, 15, 1200-1211.	1.2	58
10	Multimodal imaging of gliomas in the context of evolving cellular and molecular therapies. Advanced Drug Delivery Reviews, 2014, 76, 98-115.	13.7	48
11	EGFL7 enhances surface expression of integrin α ₅ β ₁ to promote angiogenesis in malignant brain tumors. EMBO Molecular Medicine, 2018, 10, .	6.9	33
12	Bevacizumab treatment for human glioblastoma. Can it induce cognitive impairment?. Neuro-Oncology, 2014, 16, 754-756.	1.2	23
13	Cardiometabolic risk: leg fat is protective during childhood. Pediatric Diabetes, 2016, 17, 300-308.	2.9	19
14	Improved Drug Delivery to Brain Metastases by Peptide-Mediated Permeabilization of the Blood–Brain Barrier. Molecular Cancer Therapeutics, 2019, 18, 2171-2181.	4.1	17
15	Protocol for derivation of organoids and patient-derived orthotopic xenografts from glioma patient tumors. STAR Protocols, 2021, 2, 100534.	1.2	16
16	Lack of functional normalisation of tumour vessels following anti-angiogenic therapy in glioblastoma. Journal of Cerebral Blood Flow and Metabolism, 2018, 38, 1741-1753.	4.3	15
17	Epigenetic Activity of Peroxisome Proliferator-Activated Receptor Gamma Agonists Increases the Anticancer Effect of Histone Deacetylase Inhibitors on Multiple Myeloma Cells. PLoS ONE, 2015, 10, e0130339.	2.5	11
18	Non-invasive, neurotoxic surgery reduces seizures in a rat model of temporal lobe epilepsy. Experimental Neurology, 2021, 343, 113761.	4.1	6

OLIVIER KEUNEN

#	Article	IF	CITATIONS
19	Spatially regularized estimation of the tissue homogeneity model parameters in DCEâ€MRI using proximal minimization. Magnetic Resonance in Medicine, 2019, 82, 2257-2272.	3.0	2
20	Is there a prominent role for MR spectroscopy in the clinical management of brain tumors?. Neuro-Oncology, 2020, 22, 903-904.	1.2	2
21	Current landscape and future perspectives in preclinical MR and PET imaging of brain metastasis. Neuro-Oncology Advances, 2021, 3, vdab151.	0.7	2
22	Abstract LB-518: Amplification and activation of EGFR wild-type mediates invasion of human glioblastoma in vivo. , 2012, , .		0
23	Abstract 2865: The peptide transporter K16ApoE increases drug delivery across the blood brain barrier in an experimental animal model of melanoma brain metastases. , 2017, , .		0
24	Abstract LB-314: The good drug, the bad barrier and the handy peptide: Improved treatment of experimental melanoma brain metastases using a synthetic peptide. , 2018, , .		0